Merck & Company, Inc. (MRK) Stock Forecast & Price Target
Price as of Nov 17, 2026 (intraday, delayed) · Analyst estimates retrieved Nov 17, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Merck & Company, Inc. (MRK), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Merck & Company, Inc., analysts forecast revenue rising from $64.85B in 2025 to $74.85B in 2030; the average estimate for 2030 earnings per share is $9.82; with published estimates ranging from $9.59 to $10.14; 21 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Merck & Company, Inc. (MRK) forecast — frequently asked questions
What is the analyst price target for Merck & Company, Inc.?
Analysts covering Merck & Company, Inc. (MRK) have a consensus price target of $159.45, 11.2% above the current price of $143.35. Published targets range from $105.00 to $180.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Merck & Company, Inc.'s earnings?
The average analyst estimate for Merck & Company, Inc. (MRK) earnings per share in 2030 is 9.82, with individual estimates between 9.59 and 10.14.
How much revenue is Merck & Company, Inc. expected to make?
Analysts forecast Merck & Company, Inc. (MRK) revenue of $74.85B in 2030, based on 10 published estimates.
How many analysts cover MRK?
21 analysts contribute estimates for Merck & Company, Inc. (MRK). Thin coverage makes an average less reliable.
Analyst forecasts for other Drug Manufacturers - General stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.